What Researchers Did
Researchers conducted a narrative review of published literature on radiation myelopathy following stereotactic body radiation therapy for spine metastases.
What They Found
They found that the HyTEC report recommends a spinal cord point maximal dose (Dmax) associated with a less than 5% risk of radiation myelopathy for 1-5 fraction spine SBRT. Factors like SBRT spinal cord Dmax, cumulative Dmax, and time interval between previous radiation therapy and SBRT reirradiation are linked to radiation myelopathy risk. Limited effective treatment options exist for radiation myelopathy, and none are supported by high-quality evidence.
What This Means for Canadian Patients
Canadian patients undergoing spine SBRT for metastases can be reassured that strict adherence to spinal cord dose constraints significantly reduces the risk of radiation myelopathy. However, should this rare complication occur, treatment options are limited and lack strong evidence, emphasizing the importance of preventative measures.
Canadian Relevance
This review was conducted by Canadian researchers, contributing to the understanding and management of spine SBRT complications within the Canadian healthcare system.
Study Limitations
The review highlighted a limitation in the published literature, noting limited detailed spinal cord dosimetry data for radiation myelopathy cases following spine SBRT.